Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management

Area of Science:

• Oncology
• Molecular Diagnostics
• Genomics

Background:

• Prostate cancer (PC) is a major global health concern for men.
• Current diagnostic methods like PSA testing and biopsies have limitations in accuracy and invasiveness.
• Liquid biopsy using circulating tumor DNA (ctDNA) presents a promising non-invasive alternative.

Purpose of the Study:

• To review the evolving role of ctDNA in prostate cancer management.
• To highlight ctDNA's utility in early detection, risk stratification, therapy selection, and monitoring.
• To discuss challenges and future directions for ctDNA clinical implementation.

Main Methods:

• Review of current literature on ctDNA applications in localized and metastatic PC.
• Analysis of ctDNA biomarkers including fraction, methylation, fragmentation, and mutations.
• Exploration of ctDNA's integration with imaging and traditional biomarkers.

Main Results:

• ctDNA biomarkers show potential for improved diagnostic accuracy and recurrence prediction in localized PC.
• ctDNA analysis provides insights into tumor burden, genomic alterations, and resistance in metastatic PC.
• ctDNA aids in real-time treatment response assessment and therapeutic decision-making.

Conclusions:

• ctDNA is a transformative tool with significant potential to redefine prostate cancer management.
• Overcoming challenges like low ctDNA abundance and standardization is crucial for widespread clinical adoption.
• Integrating ctDNA into precision oncology strategies promises improved patient outcomes.